
ICU Medical (ICUI) Stock Forecast & Price Target
ICU Medical (ICUI) Analyst Ratings
Bulls say
ICU Medical is well-positioned in the IV therapy market with its comprehensive portfolio and recent acquisitions of Hospira Infusion Systems and Smiths Medical. The company has reported solid revenue growth, margin expansion, and strong free cash flow in the second quarter of 2026 and has raised its guidance for the full year. Potential upside drivers include a pump upgrade cycle, market share gains, new product launches, improved pricing, and divestitures of slower growth products. Risks include gross margin pressure, regulatory challenges, and supply chain disruptions. Based on its current financial performance and potential for future growth, we maintain a Buy rating and a price target of $200 per share for ICU Medical stocks.
Bears say
ICU Medical is facing headwinds from the wind-down of an international OEM relationship, which will continue to weigh on its growth through the end of the year. Despite this, the company expects to sustain organic growth at or above 6%. However, our negative outlook is primarily driven by the company's high valuation, with a P/E multiple of 20.0x our 2027E adjusted EPS estimate. Additionally, there are potential risks to our rating and price target, including inconsistent commercial execution, competition, and geopolitical instability.
This aggregate rating is based on analysts' research of ICU Medical and is not a guaranteed prediction by Public.com or investment advice.
ICU Medical (ICUI) Analyst Forecast & Price Prediction
Start investing in ICU Medical (ICUI)
Order type
Buy in
Order amount
Est. shares
0 shares